Elawyers Elawyers
Washington| Change

Health & Beauty Technologies, Inc v. Merz Pharma, 7:18-CV-00117-FL. (2019)

Court: District Court, E.D. North Carolina Number: infdco20190911d37 Visitors: 8
Filed: Sep. 10, 2019
Latest Update: Sep. 10, 2019
Summary: ORDER GRANTING UNOPPOSED MOTION TO SEAL DOCUMENTS REGARDING REPLY IN SUPPORT OF MOTION TO DISMISS LOUISE W. FLANAGAN , District Judge . This matter is before the Court upon the Motion to Seal Documents Regarding Reply in Support of Motion to Dismiss. The reply referenced in the Motion to Seal was filed in response to Plaintiffs' Response in Opposition to Defendants' Motion to Dismiss [ECF No. 216]. It appearing to the Court, after considering the Motion to Seal, (i) that the Motion t
More

ORDER GRANTING UNOPPOSED MOTION TO SEAL DOCUMENTS REGARDING REPLY IN SUPPORT OF MOTION TO DISMISS

This matter is before the Court upon the Motion to Seal Documents Regarding Reply in Support of Motion to Dismiss. The reply referenced in the Motion to Seal was filed in response to Plaintiffs' Response in Opposition to Defendants' Motion to Dismiss [ECF No. 216].

It appearing to the Court, after considering the Motion to Seal, (i) that the Motion to Seal has been timely filed; (ii) that the granting of the Motion to Seal will not cause any undue delay or prejudice to any other parties; (iii) that granting the Motion to Seal will facilitate the efficient administration of justice; and (iv) that, for good cause shown, the Motion to Seal should be granted.

In reaching this determination, the Court (i) notes that public notice of the request to seal has been provided, and interested parties have been allowed a reasonable opportunity to object, (ii) has considered less drastic alternatives to sealing the documents, and (3) is providing specific reasons and factual findings supporting its decision to seal the documents. Specifically, it appears that the documents in question relate to highly sensitive mergers and acquisition work, including diligence, pricing, margins, and other corporate decisions. The pharmaceutical industry is extremely competitive. If these documents were to be made public, it could allow competitors to observe how Defendants determine acquisition targets and conduct diligence on those targets. This could be detrimental to Defendants' business practice, and this is the very reason why a Consent Protective Order was entered in the first place. For these reasons, maintaining the exhibits under seal outweighs the public's right to access the documents.

IT IS, THEREFORE, ORDERED, ADJUDGED AND DECREED that Defendants' Motion to Seal Documents Regarding the Reply in Support of Motion to Dismiss should be, and hereby is, granted, and the Reply and its exhibits will remain sealed.

IT IS SO ORDERED.

Source:  Leagle

Can't find what you're looking for?

Post a free question on our public forum.
Ask a Question
Search for lawyers by practice areas.
Find a Lawyer